SAFETY AND EFFICACY OF DAXOCOX®

Comparative in vitro metabolism of Enflicoxib in dogs, rats and humans: Main metabolites and proposed metabolic pathways

Enflicoxib produces three main metabolites in dogs, rats and humans. The active pyrazol metabolite showed a slow formation and elimination rate.

Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood

The most selective COX-2 inhibition and thus the efficacy of Daxocox is achieved by the active pyrazole metabolite E-6132.

Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration

Pharmacokinetic profile of the pyrazol metabolite supports weekly dosing. After 7 months of repeated weekly administrations, no trend to any significant over-accumulation was observed. When enflicoxib was administered with food, the oral bioavailability was higher than in fasted conditions

Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model

Enflicoxib posology was established as a loading dose of 8mg/kg followed by weekly maintenance doses of 4mg/kg

Long-term safety evaluation of Daxocox tablets in dogs after weekly oral administrations for seven months

No evidence of treatment-related adverse reactions. No signs of liver, renal or GI toxicity.

Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, multicentre clinical trial

Enflicoxib administered weekly for 6 weeks, at 4 mg/kg is efficacious and has a good safety profile for the treatment of OA

Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to Mavacoxib

Enflicoxib has equivalent efficacy (non-inferior) with a faster onset of action compared to mavacoxib

Efficacy and safety of enflicoxib for treatment of naturally occurring osteoarthritis in client owned dogs: A 6-months randomised, controlled, blind, parallel-group clinical field study

Enflicoxib safety and efficacy is maintained over a period of 6 months, which, together with its weekly administration, makes it a valid option for the long-term treatment of dogs with OA